Reduced potency of cytotoxic T lymphocytes from patients with high-risk myelodysplastic syndromes.

about

Reduced potency of cytotoxic T lymphocytes from patients with high-risk myelodysplastic syndromes.

Item

http://www.wikidata.org/entity/Q40592382

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Reduced potency of cytotoxic T ...... isk myelodysplastic syndromes.

@en

type

Item

label

Reduced potency of cytotoxic T ...... isk myelodysplastic syndromes.

@en

prefLabel

Reduced potency of cytotoxic T ...... isk myelodysplastic syndromes.

@en

P1476

Reduced potency of cytotoxic T ...... risk myelodysplastic syndromes

@en

P2093

Astrid Olsnes Kittang

http://www.w3.org/2001/XMLSchema#string

Jakob Theorell

http://www.w3.org/2001/XMLSchema#string

Øystein Bruserud

http://www.w3.org/2001/XMLSchema#string

P2860

Role of LAT in the granule-mediated cytotoxicity of CD8 T cells.

Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1.

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.

Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer

Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors.

Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation.

Detection and characterization of a novel subset of CD8⁺CD57⁺ T cells in metastatic melanoma with an incompletely differentiated phenotype.

Myelodysplastic syndromes: the complexity of stem-cell diseases.

Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses

The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome

P2888

s00262-016-1865-y

P304

1135-1147

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-016-1865-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yenan T Bryceson

Kristoffer Sand

P577

2016-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1050445040

http://www.w3.org/2001/XMLSchema#string

P698

27481108

http://www.w3.org/2001/XMLSchema#string